December 12, 2025

FDA Approves Inebilizumab-Cdon for Treatment of Generalized Myasthenia Gravis – Pharmacy Times

December 12, 2025

FDA Approves Amgen’s Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies – PharmExec.com

December 12, 2025

Here’s How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis – The Globe and Mail

December 12, 2025

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis – NeurologyLive

December 12, 2025

Dissecting Autoantibody Mechanisms in Myasthenia Gravis – Bioengineer.org